Previous 10 | Next 10 |
home / stock / esaly / esaly news
Eisai to Launch Digital Too "Cogmate" in Taiwan and Hong Kong for Self-Assessment of Brain Performance (Brain Health) TOKYO, Jan 13, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Taiwanese subsidiary Eisai Taiwan Inc. and Hong Kong subsidiary Eisai (Hong Kon...
Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator TOKYO, Jan 6, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into a License Agreement granting the exclusive rig...
Recording the biggest intra-day gain since June when the FDA approved its Alzheimer’s therapy Aduhelm, Biogen (NASDAQ:BIIB) shares closed at over a one-month high on the news of a potential M&A deal worth over $42B with South Korea’s Samsung Group (OTC:SSNLF). Argu...
BofA Securities is maintaining its neutral rating on Biogen (NASDAQ:BIIB) but is cutting its price target to $275 from $295 (~17% upside based on yesterday's close) after Japan refused to back its Alzheimer's drug Aduhelm (aducanumab). Analyst Geoff Meacham called the move a setback to Biogen...
Days after the company announced a nearly 50% reduction in the price of its recently approved Alzheimer's medication, Aduhelm, Oppenheimer has slashed its price target on Biogen (NASDAQ:BIIB) as much as 10%. While the company projected 50,000 new patient starts for the treatment in ...
Biogen Announces Reduced Price for Aduhelm to Improve Access For Patients With Early Alzheimer's Disease In The United States TOKYO, Dec 21, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that, effective January 1, 2022, Biogen will reduce the wholesale acquisition co...
Eisai Enters into Commercialization and Distribution Agreement with Gilead for JAK Inhibitor Filgotinib in Asia TOKYO, Dec 20, 2021 - (JCN Newswire) - Eisai Co., Ltd. today announced it has entered into an agreement with Gilead Sciences, Inc. for the commercialization and dist...
Biogen (BIIB +1.9%) and partner Eisai (OTCPK:ESALY +0.5%) plan to begin a post-marketing study of their Alzheimer's disease therapy Aduhelm (aducanumab) starting in May 2022. They plan to enroll more than 1,300 participants with early-stage Alzheimer's in the placebo-controlled study. The stu...
Eisai to Present Abstracts on Oncology Products And Pipeline at 44th Annual San Antonio Breast Cancer Symposium TOKYO, Dec 6, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its in-house discovered eri...
Galapagos is in the midst of a transformation process that is expected to result in a completely different company by 2023. Galapagos has over $5.5 billion in cash, an approved drug and a broad pipeline with a market capitalization of only $3.2 billion. Jyseleca is approved in Jap...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co. Ltd. ADR Company Name:
ESALY Stock Symbol:
OTCMKTS Market:
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria and Commitment for Funding to the 3rd Phase of Global Health Innovative Technology Fund Activities TOKYO, May 25, 2023 - (JCN Newswire) - Eisai Co., Ltd. has announced that it will grant a t...
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 TOKYO, May 24, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline durin...
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., May 16, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (b...